Cargando…
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190403/ https://www.ncbi.nlm.nih.gov/pubmed/24919804 http://dx.doi.org/10.1038/leu.2014.192 |
| _version_ | 1782338503316602880 |
|---|---|
| author | Petersen, D L Krejsgaard, T Berthelsen, J Fredholm, S Willerslev-Olsen, A Sibbesen, N A Bonefeld, C M Andersen, M H Francavilla, C Olsen, J V Hu, T Zhang, M Wasik, M A Geisler, C Woetmann, A Odum, N |
| author_facet | Petersen, D L Krejsgaard, T Berthelsen, J Fredholm, S Willerslev-Olsen, A Sibbesen, N A Bonefeld, C M Andersen, M H Francavilla, C Olsen, J V Hu, T Zhang, M Wasik, M A Geisler, C Woetmann, A Odum, N |
| author_sort | Petersen, D L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4190403 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-41904032014-10-21 B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) Petersen, D L Krejsgaard, T Berthelsen, J Fredholm, S Willerslev-Olsen, A Sibbesen, N A Bonefeld, C M Andersen, M H Francavilla, C Olsen, J V Hu, T Zhang, M Wasik, M A Geisler, C Woetmann, A Odum, N Leukemia Letter to the Editor Nature Publishing Group 2014-10 2014-07-04 /pmc/articles/PMC4190403/ /pubmed/24919804 http://dx.doi.org/10.1038/leu.2014.192 Text en Copyright © 2014 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
| spellingShingle | Letter to the Editor Petersen, D L Krejsgaard, T Berthelsen, J Fredholm, S Willerslev-Olsen, A Sibbesen, N A Bonefeld, C M Andersen, M H Francavilla, C Olsen, J V Hu, T Zhang, M Wasik, M A Geisler, C Woetmann, A Odum, N B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) |
| title | B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) |
| title_full | B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) |
| title_fullStr | B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) |
| title_full_unstemmed | B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) |
| title_short | B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) |
| title_sort | b-lymphoid tyrosine kinase (blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous t-cell lymphoma (ctcl) |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190403/ https://www.ncbi.nlm.nih.gov/pubmed/24919804 http://dx.doi.org/10.1038/leu.2014.192 |
| work_keys_str_mv | AT petersendl blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT krejsgaardt blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT berthelsenj blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT fredholms blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT willerslevolsena blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT sibbesenna blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT bonefeldcm blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT andersenmh blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT francavillac blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT olsenjv blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT hut blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT zhangm blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT wasikma blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT geislerc blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT woetmanna blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl AT odumn blymphoidtyrosinekinaseblkisanoncogeneandapotentialtargetfortherapywithdasatinibincutaneoustcelllymphomactcl |